Cart
sales@molnova.com
Serdemetan
CAS No. 881202-45-5
Serdemetan( JNJ 26854165 | JNJ26854165 | JNJ-26854165 )
Catalog No. M16390 CAS No. 881202-45-5
Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 500 | In Stock |
|
| 500MG | 1098 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSerdemetan
-
NoteResearch use only, not for human use.
-
Brief DescriptionSerdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.
-
DescriptionSerdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM; induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells; demonstrates radiosensitizing activity in vitro and in tumor xenografts.Lung Cancer Phase 1 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsJNJ 26854165 | JNJ26854165 | JNJ-26854165
-
PathwayApoptosis
-
TargetMDM2-p53
-
RecptorHDM2|Mdm2|p53
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number881202-45-5
-
Formula Weight328.4103
-
Molecular FormulaC21H20N4
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC1(NCCC2=CNC3=C2C=CC=C3)=CC=C(NC4=CC=NC=C4)C=C1
-
Chemical Name1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kojima K, et al. Mol Cancer Ther. 2010 Sep;9(9):2545-57.
2. Tabernero J, et al. Clin Cancer Res. 2011 Oct 1;17(19):6313-21.
3. Chargari C, et al. Cancer Lett. 2011 Dec 22;312(2):209-18.
4. Jones RJ, et al. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92.
molnova catalog
related products
-
NSC-66811
A potent, MDM2-p53 interaction inhibitor with Ki of 120 nM, activates p53 in cancer cells.
-
Relugolix
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity.
-
Nutlin-3
Nutlin-3 is MDM2 antagonist. Nutlin-3 inhibits the MDM2-p53 interaction (IC50 = 0.09 μM) and activates p53.
